RayKnowChina Research Map
Shortlist0

HangzhouZhejiang University School of Medicine

First Affiliated Hospital, Zhejiang University

浙江大学医学院附属第一医院

Listed for 38 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at First Affiliated Hospital, Zhejiang University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌11 papers led
  3. Hepatocellular carcinoma肝细胞癌254 papers led8 open trials led
  4. Stomach cancer胃癌63 papers led14 open trials led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Osteosarcoma骨肉瘤8 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤9 papers led1 open trial led
  8. Neuroblastoma神经母细胞瘤5 papers led1 open trial led
  9. Ewing sarcoma尤文肉瘤0 papers led
  10. Multiple myeloma多发性骨髓瘤55 papers led6 open trials led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病5 papers led13 open trials led
  12. Aplastic anaemia再生障碍性贫血1 paper led1 open trial led
  13. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症14 papers led
  14. Haemophilia A血友病 A4 papers led
  15. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  16. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  17. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病3 papers led
  18. IgG4-related diseaseIgG4相关性疾病2 papers led
  19. Myasthenia gravis重症肌无力0 papers led1 open trial led
  20. Wilson disease肝豆状核变性(Wilson 病)4 papers led1 open trial led
  21. Biliary atresia胆道闭锁2 papers led
  22. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
  23. Takayasu arteritis大动脉炎1 paper led
  24. Hepatic echinococcosis肝包虫病0 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  26. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  27. Fabry disease法布雷病2 papers led
  28. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  29. Behçet disease白塞病2 papers led
  30. Alport syndromeAlport 综合征0 papers led
  31. IgA nephropathyIgA 肾病2 papers led
  32. Gaucher disease戈谢病0 papers led1 open trial led
  33. Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
  34. Osteogenesis imperfecta成骨不全症1 paper led
  35. Primary biliary cholangitis原发性胆汁性胆管炎4 papers led
  36. Primary sclerosing cholangitis原发性硬化性胆管炎4 papers led
  37. Hirschsprung disease先天性巨结肠1 paper led
  38. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Hepatoblastoma, Chordoma, Beta thalassaemia, Fanconi anaemia, Moyamoya disease, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

8 hospitals in Hangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIRecurrent / metastatic disease
Departments in papersRadiation oncologyENT / head & neck surgery
Papers it led5
  1. An isodose-constrained automatic treatment planning strategy using a multicriteria predicted dose rating.2025Medical physicsFree full text
  2. Machine learning model for predicting recurrence following intensity-modulated radiation therapy in nasopharyngeal carcinoma.2025World journal of surgical oncologyFree full text
  3. Salidroside suppresses the activation of nasopharyngeal carcinoma cells via targeting miR-4262/GRP78 axis.2022Cell cycle (Georgetown, Tex.)Free full text
  4. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryFree full text
  5. Ceruloplasmin inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells and is negatively regulated by miR-543.2022Nucleosides, nucleotides & nucleic acids
All its trials on ClinicalTrials.gov, any status1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)5
  1. Exploiting Semantic Asymmetry to Enhance the Accuracy of Gross Tumor Volume Delineation in Nasopharyngeal Carcinoma on Planning CT2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Leveraging Semantic Asymmetry for Accurate Gross Tumor Volume Segmentation of Nasopharyngeal Carcinoma in Planning CT2025Lecture notes in computer scienceconference-paper
  3. Leveraging Semantic Asymmetry for Precise Gross Tumor Volume Segmentation of Nasopharyngeal Carcinoma in Planning CT2024arXiv (Cornell University)preprint
  4. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  5. Deep Learning-Based Multi-Modality Segmentation of Primary Gross Tumor Volume in CT and MRI for Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 11 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
11
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 3320242025: 332025

6 hospitals in Hangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  2. Recruiting
    Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05507411

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapySurgery
Departments in papersRadiation oncologyMedical oncology
Papers it led11
  1. Neoadjuvant Chemoimmunotherapy for Elderly Patients with Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.2026Annals of surgical oncology
  2. Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  3. Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrog2025European journal of medical researchFree full text
  4. Long-term outcomes after Ivor-Lewis versus McKeown esophagectomy with two-field lymphadenectomy for resectable middle or lower thoracic esophageal squamous cell carcinoma.2025Langenbeck's archives of surgeryFree full text
  5. COL8A1 Regulates Esophageal Squamous Carcinoma Proliferation and Invasion Through PI3K/AKT Pathway.2024Annals of surgical oncology
  6. ASO Author Reflections: COL8A1 Regulates Esophageal Squamous Carcinoma.2024Annals of surgical oncology
  7. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?2024Journal of cancer research and clinical oncologyFree full text
  8. STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma.2023Redox biologyFree full text
  9. Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.2022Contrast media & molecular imagingFree full text
  10. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.2022Current oncology (Toronto, Ont.)Free full text
  11. International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030.2022Esophagus : official journal of the Japan Esophageal Society
All its trials on ClinicalTrials.gov, any status16
  1. A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07142421Lead sponsorPhase 2Start 2025-08
  2. a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC StudyStatus unknownNCT06472635Lead (inferred)Start 2022-03
  3. Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of EsophagusWithdrawnNCT02033538Lead (inferred)Phase 2Start 2014-01
  4. Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal CarcinomaWithdrawnNCT02034968Lead (inferred)Phase 2Start 2014-02
  5. Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of EsophagusWithdrawnNCT02041819Lead (inferred)Phase 2Start 2014-02
  6. Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal CarcinomaWithdrawnNCT02011594Lead (inferred)Phase 2Start 2014-01
  7. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  8. Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCCRecruitingNCT05507411Study sitePhase 2Start 2022-08
  9. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  10. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  11. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  12. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  13. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  14. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  15. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  16. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)15
  1. Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology2025Research Squarepreprint
  2. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncologyretraction
  3. 1446P Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial2024Annals of Oncologyarticle
  4. Abstract 625: Remodeling of the tumor microenvironment in esophageal squamous cell carcinoma by neoadjuvant immunochemotherapy and its impact on therapeutic efficacy2024Cancer Researchconference-abstract
  5. Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced resectable esophageal squamous cell carcinoma: A prospective phase 2 study.2024Journal of Clinical Oncologyconference-abstract
  6. OA18.05 Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial2024Journal of Thoracic Oncologyconference-abstract
  7. The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma: A real world study.2024Journal of Clinical Oncologyconference-abstract
  8. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  9. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  10. Comparison of Efficacy and Safety of First‐Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta‐Analysis2023Journal of Clinical Pharmacy and Therapeuticsreview
  11. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  12. PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT12022Frontiers in Oncologyarticle
  13. 254 LYMPH NODE DISSECTION IN T1 AND T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: MINIMALLY INVASIVE ESOPHAGECTOMY VERSUS OPEN SURGERY2021Diseases of the Esophagusarticle
  14. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  15. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 254 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
254
2021–2025
Trials led
32
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 383820212022: 484820222023: 515120232024: 555520242025: 56562025

7 hospitals in Hangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-01
    Registry
    NCT06676982

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT06995105

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07039201

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07123545

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Recruiting
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07359586

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  6. Recruiting
    Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06461624

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  7. Recruiting
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05155189

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Zhengzhou

  8. Not yet recruiting
    Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07487402

    Age 19 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  9. Recruiting
    JMT106 Injection in the Treatment of Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07275073

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  10. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  11. Not yet recruiting
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07596134

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyGastroenterology / hepatology
Papers it led254
  1. Cross-modality fusion of hematology-based digital and molecular biomarkers for intelligent epidemiological screening and surveillance of hepatocellular carcinoma.2026Biosensors & bioelectronics
  2. Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single-Cell Resolution.2026Cell proliferationFree full text
  3. Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience.2026European radiology
  4. Tumor micronecrosis is a marker of poor prognosis of hepatocellular carcinoma after liver resection.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  5. A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  6. Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.2026Journal of advanced researchFree full text
  7. Systemic Inflammation-Based Staging System for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization: A Multicenter Study.2025Academic radiology
  8. Irreversible Electroporation vs. Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma: A Propensity Score Analysis.2025Academic radiology
  9. A self-assembling cytotoxic nanotherapeutic strategy for high drug loading and synergistic delivery of molecularly targeted therapies.2025Acta biomaterialia
  10. The FBXW7-RPAP2 Axis Controls the Growth of Hepatocellular Carcinoma Cells and Determines the Fate of Liver Cell Differentiation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. Galectin-1-Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  12. Diagnostic value of Gd-EOB-DTPA enhanced MRI in hepatocellular carcinoma with hyperintensity on hepatobiliary phase with cirrhosis.2025BMC cancerFree full text
  13. Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study.2025BMC cancerFree full text
  14. Therapeutic outcomes of thermal ablation versus repeated hepatic resection for recurrent hepatocellular carcinoma by using propensity score analysis: a multicenter real-world study.2025BMC cancerFree full text
  15. MRI radiomics model for predicting tumor immune microenvironment types and efficacy of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma.2025BMC medical imagingFree full text
  16. Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma.2025Cancer biology & medicineFree full text
  17. Super-enhancer-associated circPVT1 promotes malignancy of hepatocellular carcinoma via YBX1-mediated RRM2 activation.2025Cancer letters
  18. WZ4003 sensitizes hepatocellular carcinoma to OSI-027 by inhibiting ARK5-mediated autophagy.2025Cancer letters
  19. Chemokines: Orchestration of the Tumor Microenvironment and Control of Hepatocellular Carcinoma Progression.2025Cancer medicineFree full text
  20. Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study.2025Cancer medicineFree full text
  21. Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates.2025Cancer reports (Hoboken, N.J.)Free full text
  22. Diverse RNA methylation patterns in neutrophils: key drivers in hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  23. Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade.2025Clinical transplantation
  24. Fibroblast Heterogeneity in Hepatocellular Carcinoma and Identification of Prognostic Markers Based on Single-cell Transcriptome Analysis.2025Current medicinal chemistry
  25. Clinical Significance of a Novel Vasculogenic Mimicry-based Prognostic Model in Hepatocellular Carcinoma.2025Current medicinal chemistryFree full text
  26. Intraindividual comparison of CT and MRI for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma.2025European radiology
  27. Systemic chemotherapy improves outcome of hepatocellular carcinoma patients treated with transarterial chemoembolization.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  28. Nomogram for prediction of hepatocellular carcinoma recurrence after liver resection.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  29. Machine learning model stratify hepatocellular carcinoma patients into high- and low-risk recurrence or death group post curative resection.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  30. circ0006646 serves as a robust prognostic biomarker for post-transplant tumor recurrence and survival in hepatocellular carcinoma patients.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  31. Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis.2025Hepatology (Baltimore, Md.)
  32. Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.2025Hepatology (Baltimore, Md.)RCT
  33. NAE1 protein: a prognostic, immunomodulatory, and therapeutic biomarker associated with neddylation in hepatocellular carcinoma.2025International journal of biological macromolecules
  34. Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies.2025International journal of biological sciencesFree full text
  35. Radiofrequency hyperthermia enhances the antitumor efficacy of oncolytic peptide LTX-315 in liver cancer cells by activating of cGAS-STING pathway.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  36. MYBBP1A‑mediated IGFBP4 promoter methylation promotes epithelial‑mesenchymal transition and metastasis through activation of NOTCH pathway in liver cancer.2025International journal of oncologyFree full text
  37. DeepSeek-assisted LI-RADS classification: AI-driven precision in hepatocellular carcinoma diagnosis.2025International journal of surgery (London, England)Free full text
  38. Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations a prospective multicenter.2025International journal of surgery (London, England)Free full text
  39. Construction of an artificially intelligent model for accurate detection of HCC by integrating clinical, radiological, and peripheral immunological features.2025International journal of surgery (London, England)Free full text
  40. Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis.2025International journal of surgery (London, England)Free full text
  41. Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis.2025JAMA network openFree full text
  42. Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition.2025Journal of advanced researchFree full text
  43. Nucleolin as a Potent Biomarker for Predicting Tumor Recurrence among Patients with Hepatocellular Carcinoma after Transplantation.2025Journal of gastrointestinal and liver diseases : JGLD
  44. Resveratrol promotes mitophagy via the MALAT1/miR-143-3p/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma.2025Journal of integrative medicine
  45. Downregulation of MPC1 promotes HCC cell proliferation and metastasis via the STAT3 pathway.2025Journal of molecular histology
  46. Nanoliposomal PD-1 antagonist target tumor-draining lymph nodes to revitalize T cells and improve anti-tumor effect in hepatocellular carcinoma.2025Journal of nanobiotechnologyFree full text
  47. Injectable celastrol-loading emulsion hydrogel for immunotherapy of low-immunogenic cancer.2025Journal of nanobiotechnologyFree full text
  48. ViT-based quantification of intratumoral heterogeneity for predicting the early recurrence in HCC following multiple ablation.2025Liver international : official journal of the International Association for the Study of the Liver
  49. Ethical challenges and governance of artificial intelligence in hepatocellular carcinoma management : Wan DL et al. Ethical considerations in AI for hepatocellular carcinoma.2025Medical oncology (Northwood, London, England)
  50. Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system.2025Molecular cancerFree full text
  51. OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth.2025Molecular cell
  52. The deubiquitinase USP28 maintains the expression of PPARγ and its inactivation protects mice from diet-induced MASH and hepatocarcinoma.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  53. Oncolytic virus VG161 in refractory hepatocellular carcinoma.2025Nature
  54. ADSL promotes autophagy and tumor growth through fumarate-mediated Beclin1 dimethylation.2025Nature chemical biology
  55. Vision transformer-based model can optimize curative-intent treatment for patients with recurrent hepatocellular carcinoma.2025Nature communicationsFree full text
  56. ERK-USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth.2025Nature structural & molecular biology
  57. A novel cabozantinib-sulfasalazine combination targeting ferroptosis to overcome resistant immunotherapy in advanced hepatocellular carcinoma.2025Pakistan journal of pharmaceutical sciences
  58. Transferrin promotes fatty acid oxidation and liver tumor growth through PHD2-mediated PPARα hydroxylation in an iron-dependent manner.2025Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  59. Immunomodulatory impacts of thermal and pulsed field ablation therapy on hepatocellular carcinoma associated with viral hepatitis.2025Radiologie (Heidelberg, Germany)
  60. Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma.2025Science advancesFree full text
  61. Prognostic nomogram for recurrence of hepatocellular carcinoma after liver transplantation for decision making on postoperative adjuvant therapy.2025Scientific reportsFree full text
  62. Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report.2025The American journal of case reportsFree full text
  63. Survival outcomes after caudate lobectomy for hepatocellular carcinoma: systematic review and meta-analysis.2024ANZ journal of surgery
  64. Lipiodol Combined with Drug-eluting Beads Versus Drug-eluting Beads Alone for Transarterial Chemoembolization of Hepatocellular carcinoma: A Multicenter Study.2024Academic radiology
  65. Outcomes of liver transplantation for hepatocellular carcinoma in donation after circulatory death compared with donation after brain death: A systematic review and meta-analysis.2024Annals of hepatology
  66. Development and experimental validation of a machine learning-based disulfidptosis-related ferroptosis score for hepatocellular carcinoma.2024Apoptosis : an international journal on programmed cell death
  67. The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis.2024BMC cancerFree full text
  68. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.2024BMC cancerFree full text
  69. Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study.2024BMC gastroenterologyFree full text
  70. The impact of Karnofsky performance status on prognosis of patients with hepatocellular carcinoma in liver transplantation.2024BMC gastroenterologyFree full text
  71. Dynamic radiomics based on contrast-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma.2024BMC medical imagingFree full text
  72. Economic evaluation of hepatocellular carcinoma surveillance in chronic hepatitis B patients with virological remission.2024BMC public healthFree full text
  73. Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway.2024Cancer letters
  74. IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma.2024Cancer letters
  75. Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study.2024Cancer letters
  76. Predictive Prognostic Model for Hepatocellular Carcinoma Based on Seven Genes Participating in Arachidonic Acid Metabolism.2024Cancer medicineFree full text
  77. Similar usage of T-cell receptor β-chain between tumor and adjacent normal tissue in hepatocellular carcinoma.2024Cancer medicineFree full text
  78. Deep learning-based accurate diagnosis and quantitative evaluation of microvascular invasion in hepatocellular carcinoma on whole-slide histopathology images.2024Cancer medicineFree full text
  79. Clinical significance of RNA methylation in hepatocellular carcinoma.2024Cell communication and signaling : CCSFree full text
  80. Hepatitis B virus X protein promotes tumor glycolysis by downregulating lncRNA OIP5-AS1/HKDC1 in HCC.2024Cellular signalling
  81. Non-coding RNAs in hepatocellular carcinoma metastasis: Remarkable indicators and potential oncogenic mechanism.2024Computers in biology and medicine
  82. Growth differentiation factor 15: Emerging role in liver diseases.2024Cytokine
  83. Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.2024EBioMedicineFree full text
  84. Evidence of promoting effects of 6:2 Cl-PFESA on hepatocellular carcinoma proliferation in humans: An ideal alternative for PFOS in terms of environmental health?2024Environment international
  85. Environment relevant exposure of perfluorooctanoic acid accelerates the growth of hepatocellular carcinoma cells through mammalian target of rapamycin (mTOR) signal pathway.2024Environmental pollution (Barking, Essex : 1987)
  86. TRAF2 inhibits senescence in hepatocellular carcinoma cells via regulating the ROMO1/ NAD+/SIRT3/SOD2 axis.2024Free radical biology & medicine
  87. 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction.2024Free radical biology & medicine
  88. Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  89. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  90. Laparoscopic anatomical liver resection of segment 7 using a sandwich approach to the right hepatic vein (with video).2024Hepatobiliary & pancreatic diseases international : HBPD INT
  91. Concomitant hepatocellular carcinoma recurrence and mantle cell lymphoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  92. A robust genomic-based prognostic model for the assessment of cancer stemness and survival for patients with hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  93. Advanced hepatocellular carcinoma in a patient with neurofibromatosis type 1 and malignant peripheral nerve sheath tumor.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  94. Achieving laparoscopic anatomic resection for hepatocellular carcinoma by fluorescence guided positive staining of hepatic cone unit.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  95. Middle hepatic vein variation provides a safe path for anterior transection of hepatocellular carcinoma in caudate lobe.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  96. Base editing of the mutated TERT promoter inhibits liver tumor growth.2024Hepatology (Baltimore, Md.)
  97. OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.2024Hepatology internationalFree full text
  98. CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis.2024Journal of experimental & clinical cancer research : CRFree full text
  99. S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function.2024Journal of experimental & clinical cancer research : CRFree full text
  100. Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis.2024Journal of hepatology
  101. Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications.2024Journal of translational medicineFree full text
  102. The interaction between intratumoral bacteria and metabolic distortion in hepatocellular carcinoma.2024Journal of translational medicineFree full text
  103. Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.2024Journal of viral hepatitis
  104. Hepatitis B Virus-Mediated m6A Demethylation Increases Hepatocellular Carcinoma Stemness and Immune Escape.2024Molecular cancer research : MCRFree full text
  105. Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma.2024Molecular pharmaceutics
  106. PLGA micro/nanoparticle vaccination elicits non-tumor antigen specific resident memory CD8+ T cell protection from hepatocellular carcinoma.2024Nanoscale
  107. Fructose-1,6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression.2024Nature chemical biology
  108. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.2024Nature communicationsFree full text
  109. Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank.2024Nature communicationsFree full text
  110. Branched-Chain Amino Acids in Liver Diseases: Complexity and Controversy.2024NutrientsFree full text
  111. Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease.2024Science China. Life sciences
  112. Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma.2024Scientific reportsFree full text
  113. Prognostic and immune predictive roles of a novel tricarboxylic acid cycle-based model in hepatocellular carcinoma.2024Scientific reportsFree full text
  114. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.2024Signal transduction and targeted therapyFree full text
  115. The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma.2024Signal transduction and targeted therapyFree full text
  116. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.2024Small (Weinheim an der Bergstrasse, Germany)
  117. A multicenter, randomized, parallel-controlled clinical trial protocol to evaluate the safety and efficacy of irreversible electroporation compared with radiofrequency ablation for the treatment of small hepatocellular carcinoma.2024World journal of surgical oncologyFree full text
  118. Any Hepatic Lesion That Is Classified as LR-M Shall Not Be Ignored.2023AJR. American journal of roentgenology
  119. Effects of 3-HAA on HCC by Regulating the Heterogeneous Macrophages-A scRNA-Seq Analysis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  120. Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  121. Robotic anatomical segment 3 resection by extrahepatic Glissonian approach and Indocyanine green fluorescence navigation (with video).2023Asian journal of surgery
  122. Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation.2023BMC cancerFree full text
  123. MiR-652-3p promotes malignancy and metastasis of cancer cells via inhibiting TNRC6A in hepatocellular carcinoma.2023Biochemical and biophysical research communications
  124. Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1+ CD8+ T cells in HCC via blocking VEGFR2.2023Cancer scienceFree full text
  125. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.2023Cell communication and signaling : CCSFree full text
  126. The TRAF2-p62 axis promotes proliferation and survival of liver cancer by activating mTORC1 pathway.2023Cell death and differentiationFree full text
  127. Loss of Mettl3 enhances liver tumorigenesis by inducing hepatocyte dedifferentiation and hyperproliferation.2023Cell reports
  128. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.2023Cellular signalling
  129. N6 -methyladenosine-modified circSTX6 promotes hepatocellular carcinoma progression by regulating the HNRNPD/ATF3 axis and encoding a 144 amino acid polypeptide.2023Clinical and translational medicineFree full text
  130. Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma.2023Computers in biology and medicine
  131. An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons α and λ1 in HBV infection by promoting MAVS lysosomal degradation.2023EBioMedicineFree full text
  132. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.2023EBioMedicineFree full text
  133. m6A-modification regulated circ-CCT3 acts as the sponge of miR-378a-3p to promote hepatocellular carcinoma progression.2023EpigeneticsFree full text
  134. Response to Letter to the Editor regarding "Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study".2023European journal of radiology
  135. Preoperative MRI features to predict vessels that encapsulate tumor clusters and microvascular invasion in hepatocellular carcinoma.2023European journal of radiology
  136. Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study.2023European journal of radiology
  137. Comparative Analysis of Donor Liver Allograft Outcomes in Hepatocellular Carcinoma Patients Who Underwent Liver Transplant.2023Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  138. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?2023Frontiers in immunologyFree full text
  139. Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.2023GutFree full text
  140. Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.2023Hepatology (Baltimore, Md.)
  141. TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC.2023Hepatology communicationsFree full text
  142. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial.2023Hepatology communicationsFree full text
  143. Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.2023IET systems biologyFree full text
  144. Navigating the immunometabolic heterogeneity of B cells in murine hepatocellular carcinoma at single cell resolution.2023International immunopharmacology
  145. DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy.2023International journal of biological sciencesFree full text
  146. Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes.2023International journal of molecular sciencesFree full text
  147. Non-iatrogenic implantation of cutaneous metastasis from hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  148. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  149. Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  150. Single-center experience in the diagnosis and treatment of lymphoepithelioma-like hepatic carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  151. JNK/c-Jun pathway activation is essential for HBx-induced IL-35 elevation to promote persistent HBV infection.2023Journal of clinical laboratory analysisFree full text
  152. Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients.2023Journal of experimental & clinical cancer research : CRFree full text
  153. KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2.2023Journal of experimental & clinical cancer research : CRFree full text
  154. ST6GALNAC4 promotes hepatocellular carcinogenesis by inducing abnormal glycosylation.2023Journal of translational medicineFree full text
  155. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.2023MedicineFree full text
  156. An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma.2023Molecular carcinogenesis
  157. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function.2023Nature cell biology
  158. Nucleus-exported CLOCK acetylates PRPS to promote de novo nucleotide synthesis and liver tumour growth.2023Nature cell biology
  159. Bigelovin inhibits hepatocellular carcinoma cell growth and metastasis by regulating the MAPT-mediated Fas/FasL pathway.2023Neoplasma
  160. WDR74 serves as a novel therapeutic target by its oncogenic role in hepatocellular carcinoma.2023Pathology, research and practice
  161. Silencing of TRAF5 enhances necroptosis in hepatocellular carcinoma by inhibiting LTBR-mediated NF-κB signaling.2023PeerJFree full text
  162. CT radiomics for noninvasively predicting NQO1 expression levels in hepatocellular carcinoma.2023PloS oneFree full text
  163. Long-term outcomes of endoscopic ultrasound-guided laser ablation for liver tumors in the caudate lobe: 5 years of experience.2023Scandinavian journal of gastroenterology
  164. A novel prognostic model for hepatocellular carcinoma based on pyruvate metabolism-related genes.2023Scientific reportsFree full text
  165. ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression.2023Signal transduction and targeted therapyFree full text
  166. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.2023Stem cell research & therapyFree full text
  167. Robotic versus laparoscopic liver resection in posterosuperior region: a retrospective study of consecutive cases.2023Surgical endoscopy
  168. HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.2023Virology journalFree full text
  169. Circ_0000291 contributes to hepatocellular carcinoma tumorigenesis by binding to miR-1322 to up-regulate UBE2T.2022Annals of hepatology
  170. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.2022BMC cancerFree full text
  171. Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis.2022BMC infectious diseasesFree full text
  172. Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  173. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  174. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.2022Cancer immunology, immunotherapy : CIIFree full text
  175. Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma.2022Cancer medicineFree full text
  176. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.2022Cancer research
  177. Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma.2022Cancer scienceFree full text
  178. Drug delivery strategy in hepatocellular carcinoma therapy.2022Cell communication and signaling : CCSFree full text
  179. Exosomal hsa_circ_0004658 derived from RBPJ overexpressed-macrophages inhibits hepatocellular carcinoma progression via miR-499b-5p/JAM3.2022Cell death & diseaseFree full text
  180. SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.2022CellsFree full text
  181. Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines.2022Cytokine
  182. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  183. The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.2022Frontiers in immunologyFree full text
  184. Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.2022Future oncology (London, England)
  185. Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  186. SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  187. Ultrasound-guided in vivo porcine liver ablation with nanosecond pulsed electric fields.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  188. High nuclear ABCG1 expression is a poor predictor for hepatocellular carcinoma patient survival.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  189. Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.2022International journal of biological sciencesFree full text
  190. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.2022International journal of medical sciencesFree full text
  191. Expression, Prognostic Value, and Functional Mechanism of Polarity-Related Genes in Hepatocellular Carcinoma.2022International journal of molecular sciencesFree full text
  192. Histological tumor micronecrosis in resected specimens after R0 hepatectomy for hepatocellular carcinomas is a factor in determining adjuvant TACE: A retrospective propensity score-matched study.2022International journal of surgery (London, England)
  193. Nanocarrier-Based Tumor-Targeting Drug Delivery Systems for Hepatocellular Carcinoma Treatments: Enhanced Therapeutic Efficacy and Reduced Drug Toxicity.2022Journal of biomedical nanotechnology
  194. Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.2022Journal of hepatology
  195. HO-1 Protects Remnant Liver against Dysfunction after Major Hepatectomy in Humans.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  196. A Nomogram Estimation for the Risk of Microvascular Invasion in Hepatocellular Carcinoma Patients Meeting the Milan Criteria.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  197. Impact of hepatitis B surface antigen positive grafts on liver transplantation in patients with benign and malignant liver disease.2022Journal of medical virology
  198. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients.2022Journal of translational medicineFree full text
  199. Association of Plasma Fibrinogen Levels on Postoperative Day 1 with 2-Year Survival of Orthotopic Liver Transplantation for HBV-Related HCC.2022Laboratory medicine
  200. Response to the clinical significance and prognostic value of 3-mercaptopyruvate sulfurtransferase in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  201. 3-Mercaptopyruvate sulfurtransferase represses tumour progression and predicts prognosis in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  202. Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation.2022Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  203. Triptolide-mediated downregulation of FLIPS in hepatoma cells occurs at the post-transcriptional level independently of proteasome-mediated pathways.2022Medical oncology (Northwood, London, England)Free full text
  204. Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth.2022Nature cell biology
  205. FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion.2022Nature communicationsFree full text
  206. Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma.2022Nature metabolism
  207. Multi-Omics and Artificial Intelligence-Guided Data Integration in Chronic Liver Disease: Prospects and Challenges for Precision Medicine.2022Omics : a journal of integrative biology
  208. HFE promotes mitotic cell division through recruitment of cytokinetic abscission machinery in hepatocellular carcinoma.2022Oncogene
  209. Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity.2022Oncogene
  210. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.2022OncoimmunologyFree full text
  211. Chlorogenic Acid, the Main Antioxidant in Coffee, Reduces Radiation-Induced Apoptosis and DNA Damage via NF-E2-Related Factor 2 (Nrf2) Activation in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  212. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.2022Scientific reportsFree full text
  213. Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease.2022Scientific reportsFree full text
  214. Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma.2022Signal transduction and targeted therapyFree full text
  215. Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis.2022The International journal of biological markers
  216. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis.2022Transplantation reviews (Orlando, Fla.)
  217. A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study.2021BMC cancerFree full text
  218. Cyclin-dependent kinase 19 upregulation correlates with an unfavorable prognosis in hepatocellular carcinoma.2021BMC gastroenterologyFree full text
  219. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database.2021BMC gastroenterologyFree full text
  220. Continuous elevation of procalcitonin in cirrhosis combined with hepatic carcinoma: a case report.2021BMC infectious diseasesFree full text
  221. In silico analysis suggests disruption of interactions between HAMP from hepatocytes and SLC40A1 from macrophages in hepatocellular carcinoma.2021BMC medical genomicsFree full text
  222. Differentially Expressed Long Noncoding RNAs Involved in FUBP1 Promoting Hepatocellular Carcinoma Cells Proliferation.2021BioMed research internationalFree full text
  223. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.2021Biochemical pharmacology
  224. MiR-9-5p promotes cell proliferation and migration of hepatocellular carcinoma by targeting CPEB3.2021Biomarkers in medicine
  225. The mechanistic, diagnostic and therapeutic novel nucleic acids for hepatocellular carcinoma emerging in past score years.2021Briefings in bioinformatics
  226. Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.2021Cancer communications (London, England)Free full text
  227. Landscape analysis of lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in liver cancer through the PARP1/p53 axis.2021Cancer letters
  228. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.2021Cancer letters
  229. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.2021Cancer medicineFree full text
  230. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  231. Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data.2021Clinical and translational medicineFree full text
  232. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma.2021Experimental biology and medicine (Maywood, N.J.)Free full text
  233. Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field.2021Frontiers of medicine
  234. XIAP, commonly targeted by tumor suppressive miR-3607-5p and miR-3607-3p, promotes proliferation and inhibits apoptosis in hepatocellular carcinoma.2021Genomics
  235. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  236. Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  237. Recent advances in immunotherapy for hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  238. Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.2021Hepatology (Baltimore, Md.)Free full text
  239. REPLY.2021Hepatology (Baltimore, Md.)
  240. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.2021International immunopharmacology
  241. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.2021International journal of biological sciencesFree full text
  242. Fusion imaging-guided radiofrequency ablation for residual hepatocellular carcinoma invisible on ultrasound after transcatheter arterial chemoembolization.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  243. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.2021Journal of cellular and molecular medicineFree full text
  244. Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis.2021Journal of cellular and molecular medicineFree full text
  245. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.2021Journal of cellular biochemistry
  246. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma.2021Journal of cellular physiology
  247. Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma.2021Journal of clinical laboratory analysisFree full text
  248. MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway.2021Journal of experimental & clinical cancer research : CRFree full text
  249. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis.2021Journal of experimental & clinical cancer research : CRFree full text
  250. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.2021Journal of translational medicineFree full text
  251. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.2021Medical oncology (Northwood, London, England)
  252. EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation.2021Oncogene
  253. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.2021TheranosticsFree full text
  254. Quantitative Ultrasound Elastography Methods in Focal Liver Lesions Including Hepatocellular Carcinoma: From Diagnosis to Prognosis.2021Ultrasound quarterly
Chinese-language papers (not in the count)1
  1. [Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status57
  1. TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCCStatus unknownNCT04992143Lead sponsorPhase 2Start 2021-08
  2. A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver CancerStatus unknownNCT05371873Lead sponsorStart 2021-03
  3. SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTTStatus unknownNCT04387695Lead sponsorPhase 3Start 2020-04
  4. Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular CarcinomaNot yet recruitingNCT07487402Lead (inferred)Early phase 1Start 2026-03
  5. Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT07123545Lead (inferred)Phase 1/Phase 2Start 2025-08
  6. A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT07039201Lead (inferred)N/AStart 2025-06
  7. Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT06676982Lead (inferred)Phase 1Start 2025-01
  8. Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaRecruitingNCT07359586Lead (inferred)Start 2025-11
  9. Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT06995105Lead (inferred)Phase 1/Phase 2Start 2025-04
  10. Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT06461624Lead (inferred)Phase 1Start 2024-07
  11. A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular CarcinomaRecruitingNCT05155189Lead (inferred)Phase 1Start 2022-02
  12. Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC PatientsStatus unknownNCT06577272Lead (inferred)Start 2024-09
  13. Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Lead (inferred)Phase 2Start 2023-04
  14. Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC PatientsCompletedNCT05213221Lead (inferred)Phase 2Start 2022-03
  15. HCC Staging Modified by Tumor MicronecrosisCompletedNCT05739110Lead (inferred)Start 2022-07
  16. Prognostic Models for HCC Based on Tumor MicronecrosisStatus unknownNCT05837065Lead (inferred)Start 2022-09
  17. Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular CarcinomaActive, not recruitingNCT04756648Lead (inferred)Phase 1Start 2021-03
  18. IMC001 for Clinical Research on Advanced Digestive System MalignanciesStatus unknownNCT05028933Lead (inferred)Phase 1Start 2021-09
  19. SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular CarcinomaCompletedNCT04930315Lead (inferred)Phase 2Start 2021-09
  20. A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionStatus unknownNCT04981665Lead (inferred)Phase 2Start 2021-11
  21. Perioperative Therapy for Hepatocellular CarcinomaTerminatedNCT04653389Lead (inferred)Phase 2Start 2020-12
  22. Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC PatientsCompletedNCT04418401Lead (inferred)Phase 1Start 2020-06
  23. AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaStatus unknownNCT04368182Lead (inferred)Phase 1Start 2020-04
  24. Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular CarcinomasCompletedNCT05352204Lead (inferred)Start 2020-04
  25. Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver TransplantationStatus unknownNCT04232722Lead (inferred)Phase 2Start 2020-01
  26. Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCCStatus unknownNCT04174781Lead (inferred)Phase 2Start 2019-11
  27. Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138Lead (inferred)Start 2019-02
  28. Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver TransplantStatus unknownNCT04035876Lead (inferred)Phase 1/Phase 2Start 2019-07
  29. 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03980288Lead (inferred)Phase 1Start 2019-07
  30. A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery RecurrenceTerminatedNCT03945799Lead (inferred)Phase 1/Phase 2Start 2019-04
  31. Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver TransplantationWithdrawnNCT02580253Lead (inferred)Phase 2Start 2017-11
  32. Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1WithdrawnNCT02129322Lead (inferred)Phase 2Start 2015-07
  33. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Study siteN/AStart 2026-10
  34. JMT106 Injection in the Treatment of Advanced Solid TumorsRecruitingNCT07275073Study sitePhase 1Start 2025-09
  35. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  36. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  37. A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06590246Study sitePhase 1/Phase 2Start 2024-09
  38. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  39. A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Study sitePhase 2Start 2021-01
  40. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  41. Clinical Study of VG161 in Subjects with Advanced Primary Liver CancerStatus unknownNCT04806464Study sitePhase 1Start 2021-03
  42. A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular CarcinomaTerminatedNCT04635527Study sitePhase 1Start 2020-12
  43. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  44. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  45. Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Study sitePhase 1Start 2019-08
  46. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  47. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  48. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  49. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  50. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  51. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  52. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma HugeStatus unknownNCT03277716Study siteN/AStart 2017-12
  53. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  54. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11
  55. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07
  56. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03
  57. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 63 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
63
2021–2025
Trials led
24
any status, ClinicalTrials.gov
Open trials led
14
recruiting or about to
Open trials as a site
14
led by another institution
Papers led per year
2021: 121220212022: 121220222023: 8820232024: 121220242025: 18182025

9 hospitals in Hangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 28

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07525765

    Age 18 years to 90 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07104214

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07139418

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07175155

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou

  5. Recruiting
    High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07307560

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  6. Recruiting
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07359586

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  7. Recruiting
    Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06728878

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  8. Recruiting
    Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06728891

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  9. Recruiting
    Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06736847

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  10. Recruiting
    Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06821048

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  11. Recruiting
    CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06937567

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  12. Not yet recruiting
    18F-FAPI PET/CT and MRI in Gastric Cancer
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07510867

    Age 20 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  13. Not yet recruiting
    Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07621562

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  14. Not yet recruiting
    High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07791979

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  15. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  16. Recruiting
    IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07483554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  17. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  18. Recruiting
    COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06796764

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  19. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  20. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  21. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  22. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  23. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  24. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  25. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

  26. Not yet recruiting
    SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2026-12
    Registry
    NCT07903857

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  27. Not yet recruiting
    Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07904260

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  28. Not yet recruiting
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05970627

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseChemotherapy & combined treatmentImaging & AI
Departments in papersMedical oncologyGastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led63
  1. Helicobacter pylori-naïve status is associated with poor prognosis and aggressive pathological features in undifferentiated-type gastric cancer: a multi-center retrospective cohort study.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  2. Blood Biomarker-Based Predictive Indicator for Liver Metastasis in Alpha-Fetoprotein-Producing Gastric Cancer and Multi-Omics Tumor Microenvironment Insights.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Entropy-Driven Nucleic Acid Amplifier Based on Spatial Confinement as a "Booster" for Detection of Extracellular Vesicle MicroRNAs to Diagnose Gastric Cancer and Monitor Therapeutic Response.2025Analytical chemistry
  4. Deciphering mismatch repair protein expression variability in gastric cancer: clinical and prognostic implications.2025BMC cancerFree full text
  5. The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.2025BMC cancerRCTFree full text
  6. Prediction of pathological response to neoadjuvant immunochemotherapy with baseline and post-treatment 18F-FDG PET imaging biomarkers in patients with locally advanced gastric cancer.2025BMC cancerFree full text
  7. Relationship between the degree of Helicobacter pylori infection and miR-155 and miR-543 expression levels in gastric cancer.2025BMC gastroenterologyFree full text
  8. The clinical benefits of [18F]AlF-NOTA-octreotide PET/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: comparison of [18F]FDG PET/CT.2025BMC medical imagingFree full text
  9. CircSRPK1 mediated by the exon junction complex promotes gastric cancer progression by interacting with hnRNP A2B1 to regulate RON mRNA alternative splicing.2025Cancer letters
  10. FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  11. S100A8/A9-MCAM signaling promotes gastric cancer cell progression via ERK-c-Jun activation.2025In vitro cellular & developmental biology. AnimalFree full text
  12. PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer.2025International journal of biological macromolecules
  13. TGF-βI/FERMT2/COL6A1 Reciprocal Loop Drives Tumor-Stroma Crosstalk and Promotes Peritoneal Metastasis in Gastric Cancer.2025International journal of biological sciencesFree full text
  14. High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.2025Journal of cachexia, sarcopenia and muscleRCTFree full text
  15. AC129507.1 is a ferroptosis-related target identified by a novel mitochondria-related lncRNA signature that is involved in the tumor immune microenvironment in gastric cancer.2025Journal of translational medicineFree full text
  16. Microbial and Metabolomic Variations Correlated With Gastric Cancer Subtypes and Prognosis.2025MicrobiologyOpenFree full text
  17. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  18. TPOAb indicates neuroendocrine tumor in autoimmune gastritis: A retrospective study of 91 patients.2025The American journal of the medical sciences
  19. Effect of thoracic size on postoperative outcomes in transabdominal gastrectomy for Siewert type II/III adenocarcinoma of the esophagogastric junction.2025World journal of surgical oncologyFree full text
  20. Examining the role of resilience in the relationship between social support and fear of recurrence among patients with gastric cancer on chemotherapy: a cross-sectional study in Jiangsu, China.2024BMJ openFree full text
  21. MEF2D facilitates liver metastasis of gastric cancer cells through directly inducing H1X under IL-13 stimulation.2024Cancer letters
  22. Association of metabolic syndrome and frailty with postoperative complications in older gastric cancer patients: A body composition perspective.2024Cancer medicineFree full text
  23. Downregulation of malic enzyme 3 facilitates progression of gastric carcinoma via regulating intracellular oxidative stress and hypoxia-inducible factor-1α stabilization.2024Cellular and molecular life sciences : CMLSFree full text
  24. Stem cell landscape aids in tumor microenvironment identification and selection of therapeutic agents in gastric cancer.2024Cellular signalling
  25. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  26. DNA hypomethylation of INHBA promotes tumor progression and predicts prognosis and immune status of gastric cancer.2024HereditasFree full text
  27. MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation.2024Journal of experimental & clinical cancer research : CRFree full text
  28. KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner.2024Journal of translational medicineFree full text
  29. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.2024Scandinavian journal of gastroenterology
  30. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.2024Scientific reportsFree full text
  31. Development and evaluation of the Newstage system: integrating tumor regression grade and lymph node status for improved prognostication in neoadjuvant treatment of gastric cancer.2024World journal of surgical oncologyFree full text
  32. Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  33. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.2023Annals of surgical oncologyFree full text
  34. The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer.2023Cancer medicineFree full text
  35. Prognostic effects of the gastric mucosal microbiota in gastric cancer.2023Cancer scienceFree full text
  36. Therapeutic effects and safety of apatinib mesylate on patients with gastric carcinoma peritoneal metastasis in SOX scheme.2023European review for medical and pharmacological sciences
  37. Proteomic profiling of gastric cancer with peritoneal metastasis identifies a protein signature associated with immune microenvironment and patient outcome.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  38. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.2023Medicine
  39. Aldo-keto Reductase 1B10 Restrains Cell Migration, Invasion, and Adhesion of Gastric Cancer via Regulating Integrin Subunit Alpha 5.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  40. A multicenter study on the preoperative prediction of gastric cancer microsatellite instability status based on computed tomography radiomics.2022Abdominal radiology (New York)
  41. Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing.2022Clinical and translational medicineFree full text
  42. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.2022Frontiers in immunologyFree full text
  43. Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers.2022Frontiers in immunologyFree full text
  44. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.2022Frontiers in immunologyFree full text
  45. Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.2022International journal of biological sciencesFree full text
  46. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.2022JAMA network openRCTFree full text
  47. Comparison of Clinical Efficacy Between Laparoscopic and Open Distal Gastrectomy in the Treatment of Gastric Carcinoma: A Meta-Analysis.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  48. Lymphoepithelioma-like Carcinoma of the Stomach: A Case Successfully Treated with Chemotherapy.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  49. Microbiota and metabolites alterations in proximal and distal gastric cancer patients.2022Journal of translational medicineFree full text
  50. Host miRNAs-microbiota interactions in gastric cancer.2022Journal of translational medicineFree full text
  51. Circular RNAs in endometrial carcinoma (Review).2022Oncology reportsFree full text
  52. Confocal laser endomicroscopy under propofol-based sedation for early gastric cancer and pre-cancerous lesions is associated with better diagnostic accuracy: a retrospective cohort study in China.2021BMC anesthesiologyFree full text
  53. CT differentiation of gastric ectopic pancreas from gastric stromal tumor.2021BMC gastroenterologyFree full text
  54. The impact of a prior malignancy on outcomes in gastric cancer patients.2021Cancer medicineFree full text
  55. Impact of prior cancer history on survival of patients with gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  56. Comment on: "Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric cancer, 2021 Aug 11" by Iwatsuki et al.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  57. Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  58. Comment on: "Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study. Gastric cancer, 2021 Aug 5" by Kim et al.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  59. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  60. Global Patterns and Trends in Gastric Cancer Incidence Rates (1988-2012) and Predictions to 2030.2021Gastroenterology
  61. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.2021Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  62. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.2021Nature communicationsFree full text
  63. Carcinosarcoma of the stomach with alpha-fetoprotein-producing hepatoid adenocarcinoma: an unexpected combination of two rare subtypes of gastric cancer in one tumor.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)2
  1. [Amphicrine carcinoma of the stomach: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Concept and clinicopathological features of gastrointestinal very well differentiated adenocarcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status63
  1. Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric CancerNot yet recruitingNCT07621562Lead sponsorPhase 2Start 2026-06
  2. AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric CancerRecruitingNCT07525765Lead sponsorStart 2026-04
  3. 18F-FAPI PET/CT and MRI in Gastric CancerNot yet recruitingNCT07510867Lead sponsorStart 2026-05
  4. Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.Status unknownNCT04778839Lead sponsorPhase 1Start 2021-03
  5. The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.Status unknownNCT04065282Lead sponsorPhase 2Start 2019-08
  6. High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary DiseaseNot yet recruitingNCT07791979Lead (inferred)N/AStart 2026-08
  7. Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated GastroscopyRecruitingNCT07104214Lead (inferred)Start 2025-08
  8. Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese PatientsRecruitingNCT07175155Lead (inferred)N/AStart 2025-10
  9. Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaRecruitingNCT07359586Lead (inferred)Start 2025-11
  10. The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing GastrectomyRecruitingNCT07139418Lead (inferred)Start 2025-10
  11. High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea PatientsRecruitingNCT07307560Lead (inferred)N/AStart 2025-12
  12. Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal GastrectomyRecruitingNCT06728891Lead (inferred)Start 2024-05
  13. Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid TumorsRecruitingNCT06821048Lead (inferred)Phase 1Start 2024-07
  14. CDH17 CAR-T Therapy in Advanced Malignant Solid TumorsRecruitingNCT06937567Lead (inferred)Early phase 1Start 2024-12
  15. Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric CancerRecruitingNCT06736847Lead (inferred)Start 2024-05
  16. Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric CancerRecruitingNCT06728878Lead (inferred)Start 2024-05
  17. Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese PatientsCompletedNCT06812403Lead (inferred)Phase 2Start 2025-02
  18. COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese PatientsCompletedNCT06804876Lead (inferred)Phase 2Start 2025-02
  19. High-flow Nasal Cannula Oxygenation in Sedated Endoscopy for High-risk Obstructive Sleep Apnea PatientsCompletedNCT07155330Lead (inferred)N/AStart 2025-09
  20. Validation of a Model for Predicting Duodenal Stump Leakage After GastrectomyActive, not recruitingNCT06807372Lead (inferred)Start 2024-09
  21. In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric CancerStatus unknownNCT05842187Lead (inferred)N/AStart 2023-03
  22. A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid TumorsCompletedNCT05396300Lead (inferred)Phase 1Start 2022-05
  23. IMC001 for Clinical Research on Advanced Digestive System MalignanciesStatus unknownNCT05028933Lead (inferred)Phase 1Start 2021-09
  24. TAS-102 and Anlotinib in ≥3 Lines mGCStatus unknownNCT05029102Lead (inferred)Phase 2Start 2021-09
  25. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  26. IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingNCT07483554Study sitePhase 2Start 2026-04
  27. Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude RegionsNot yet recruitingNCT07904260Study siteN/AStart 2026-11
  28. SND002 Cell Injection in Participants With Advanced Malignant Solid TumorsNot yet recruitingNCT07903857Study sitePhase 1Start 2026-12
  29. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  30. COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical TrialRecruitingNCT06796764Study siteN/AStart 2025-04
  31. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  32. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  33. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  34. Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaNot yet recruitingNCT05970627Study sitePhase 2Start 2023-07
  35. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  36. A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06043466Study sitePhase 1Start 2023-08
  37. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  38. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Study sitePhase 1Start 2022-06
  39. Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics IntegrationStatus unknownNCT06396143Study siteStart 2024-07
  40. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  41. Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingNCT05715931Study sitePhase 2Start 2023-05
  42. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  43. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  44. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  45. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  46. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Study sitePhase 2Start 2021-08
  47. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  48. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  49. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  50. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  51. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  52. Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Status unknownNCT04515615Study sitePhase 2Start 2020-09
  53. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  54. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  55. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  56. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  57. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  58. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  59. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  60. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  61. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  62. Study of Metatinib Tromethamine TabletStatus unknownNCT02650375Study sitePhase 1Start 2015-10
  63. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric CarcinomaCompletedNCT01364376Study siteN/AStart 2011-06

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Hangzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 2220232024: 1120242025: 112025

22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led8
  1. Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression.2025Journal of translational medicine
  2. PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes.2024International journal of biological sciences
  3. A risk score model based on endoplasmic reticulum stress related genes for predicting prognostic value of osteosarcoma.2023BMC musculoskeletal disorders
  4. Development of a novel vasculogenic mimicry-associated gene signature for the prognostic assessment of osteosarcoma patients.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. LINC00313 facilitates osteosarcoma carcinogenesis and metastasis through enhancing EZH2 mRNA stability and EZH2-mediated silence of PTEN expression.2022Cellular and molecular life sciences : CMLS
  6. Circular RNA ROCK1, a novel circRNA, suppresses osteosarcoma proliferation and migration via altering the miR-532-5p/PTEN axis.2022Experimental & molecular medicine
  7. MCAM is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration.2022Journal of clinical laboratory analysis
  8. Primary fibroblastic osteosarcoma of sternum: A case report.2022Medicine
Chinese-language papers (not in the count)1
  1. [Adamantinoma-like Ewing sarcoma of duodenal ameoblastoma with EWSR1::ERG gene fusion: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)4
  1. Nomograms for predicting overall survival and cancer-specific survival of chondroblastic osteosarcoma patients.2020Journal of surgical oncology
  2. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.2019Journal of cellular biochemistry
  3. Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Proliferation and Metastasis of Osteosarcoma Cells by Targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b.2019Medical science monitor : international medical journal of experimental and clinical research
  4. Nano-pulse stimulation (NPS) ablate tumors and inhibit lung metastasis on both canine spontaneous osteosarcoma and murine transplanted hepatocellular carcinoma with high metastatic potential.2017Oncotarget

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 9 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.7%.

Papers led
9
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 2220242025: 112025

16 hospitals in Hangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT04933669

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicine
Papers it led9
  1. Clinicopathological features and treatment of gastrointestinal schwannomas.2025World journal of gastroenterology
  2. Pancreatic giant malignancy simulating a gastrointestinal stromal tumor.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  3. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.2024Scandinavian journal of gastroenterology
  4. Reassessment of the recurrence risk of primary gastrointestinal stromal tumour after complete resection.2023Scandinavian journal of gastroenterology
  5. Elevated preoperative controlling nutritional status (CONUT) scores as a predictor of postoperative recurrence in gastrointestinal stromal tumors.2022Journal of surgical oncology
  6. Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review.2022Medicine
  7. Endoscopic treatment can be a viable therapeutic option for esophageal gastrointestinal stromal tumors.2022Scandinavian journal of gastroenterology
  8. CT differentiation of gastric ectopic pancreas from gastric stromal tumor.2021BMC gastroenterologyFree full text
  9. Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Earlier papers (2016–2020)6
  1. Gastrointestinal stromal tumour with an unusual presentation as a huge prostatic mass: a case report.2019ANZ journal of surgery
  2. Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.2019Medicine
  3. Robot-assisted laparoscopic surgery for abdominal metastatic melanoma mimicking a gastrointestinal stromal tumor: A case report and review of the literature.2018Medicine
  4. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.2018Scandinavian journal of gastroenterology
  5. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.2016Oncology reports
  6. Comparison of endoscopic submucosal dissection and surgery for the treatment of gastric submucosal tumors originating from the muscularis propria layer: a single-center study (with video).2016Surgical endoscopy
All its trials on ClinicalTrials.gov, any status4
  1. Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal TumorsRecruitingNCT04933669Lead sponsorPhase 2Start 2021-09
  2. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  3. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  4. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

8 hospitals in Hangzhou for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06852807

    Age Not stated to 18 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Hangzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Adamantinoma-like Ewing sarcoma of duodenal ameoblastoma with EWSR1::ERG gene fusion: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 55 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 3.3%.

Papers led
55
2021–2025
Trials led
14
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
19
led by another institution
Papers led per year
2021: 7720212022: 141420222023: 131320232024: 7720242025: 10102025

9 hospitals in Hangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 25

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06644118

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06463717

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2022-05
    Registry
    NCT04657861

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
    Phase
    Early phase 1
    Started
    2021-11
    Registry
    NCT04662294

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Not yet recruiting
    A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
    Phase
    Early phase 1
    Started
    2021-01
    Registry
    NCT04670055

    Age 30 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  6. Not yet recruiting
    A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
    Phase
    Early phase 1
    Started
    2020-12
    Registry
    NCT04541368

    Age 30 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  7. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  8. Recruiting
    A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
    Phase
    Phase 1
    Started
    2026-02
    Registry
    NCT07409246

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin

  9. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  10. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  11. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  12. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  13. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  14. Recruiting
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06520176

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou

  15. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  16. Recruiting
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05565807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  17. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  18. Recruiting
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    Phase
    Phase 4
    Started
    2023-10
    Registry
    NCT06057402

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan

  19. Recruiting
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06182696

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan

  20. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  21. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  22. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  23. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  24. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  25. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRelapse & resistanceCAR-T & cell therapyDiagnosis, MRD & risk
Departments in papersMedical oncologyRadiology / nuclear medicine
Papers it led55
  1. Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy.2026Bone marrow transplantation
  2. Evaluation of iMS-IP assay for the detection and typing of monoclonal immunoglobulins.2026Clinica chimica acta; international journal of clinical chemistry
  3. Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5/8-CXCR2 axis.2026HaematologicaFree full text
  4. MRD contamination in peripheral blood autologous stem cell grafts: implications for relapse and prognosis in multiple myeloma.2026Leukemia & lymphoma
  5. The Ratio of Serum Urea Nitrogen to Albumin Is a Better Predictor of Overall Survival in Multiple Myeloma Patients than Urea Nitrogen Alone.2025Acta haematologicaFree full text
  6. Serum ferritin can serve as a biomarker for the prognosis and increased the prognostic predictive value of ISS/RISS in multiple myeloma patients.2025Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  7. Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study.2025Bone marrow transplantationFree full text
  8. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.2025CancerFree full text
  9. Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells.2025Chinese medical journalFree full text
  10. N6-methyladenosine-mediated upregulation of H19 promotes resistance to bortezomib by modulating the miR-184/CARM1 axis in multiple myeloma.2025Clinical and experimental medicineFree full text
  11. Determining the factors affecting bortezomib's adverse events in the treatment of newly diagnosed multiple myeloma.2025Hematology (Amsterdam, Netherlands)
  12. Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.2025International journal of hematology
  13. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2025Journal for immunotherapy of cancerFree full text
  14. Di-(2-ethylhexyl) phthalate (DEHP) and its metabolite promote multiple myeloma progression and bortezomib resistance.2025Journal of hazardous materials
  15. The development and validation of a liquid chromatography tandem mass spectrometry method for the quantification of selinexor and its application in Chinese multiple myeloma patients.2024Analytical methods : advancing methods and applications
  16. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.2024BiomoleculesFree full text
  17. Disruption of DNA-PKcs-mediated cGAS retention on damaged chromatin potentiates DNA damage-inducing agent-induced anti-multiple myeloma activity.2024British journal of cancerFree full text
  18. The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.2024Cancer biology & therapyFree full text
  19. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.2024Cancer medicineFree full text
  20. Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab.2024Cancer scienceFree full text
  21. Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity.2023Archives of toxicology
  23. TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.2023Blood advancesFree full text
  24. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy.2023Bone marrow transplantation
  25. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.2023British journal of haematology
  26. Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma.2023Cancer immunology, immunotherapy : CIIFree full text
  27. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.2023Cytotherapy
  28. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.2023Frontiers in immunologyFree full text
  29. Calcium silicate/bortezomib combinatory therapy for multiple myeloma.2023Journal of materials chemistry. B
  30. The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.2023LeukemiaFree full text
  31. Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma.2023Leukemia & lymphoma
  32. New diagnostic strategy for multiple myeloma: A review.2023MedicineFree full text
  33. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.2023The Lancet. Haematology
  34. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.2023Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  35. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).2022Annals of hematologyFree full text
  36. Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma.2022Cancer researchFree full text
  37. NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma.2022Cell death & diseaseFree full text
  38. Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.2022Clinical epigeneticsFree full text
  39. Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.2022Current oncology (Toronto, Ont.)Free full text
  40. A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials.2022Haematologica
  41. High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma.2022Journal of Zhejiang University. Science. BFree full text
  42. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.2022Nature communicationsFree full text
  43. RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways.2022OncogeneFree full text
  44. Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis.2022OncoimmunologyFree full text
  45. Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients.2022Scientific reportsFree full text
  46. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
  47. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
  48. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
  49. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019.2021BMC cancerFree full text
  50. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  51. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma.2021Blood cancer journalFree full text
  52. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial.2021Bone marrow transplantation
  53. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.2021Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  54. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels.2021Cytokine
  55. Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.2021Molecular therapy : the journal of the American Society of Gene TherapyFree full text
Chinese-language papers (not in the count)3
  1. [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  2. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.2023Journal of Zhejiang University. Science. BFree full text
  3. [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].2022Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status69
  1. Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or NotRecruitingNCT06463717Lead sponsorStart 2023-12
  2. B Cell Maturation Antigen(BMCA)-Targeted CAR-T for Refractory/Relapsed Multiple MyelomaStatus unknownNCT03931421Lead sponsorPhase 2Start 2019-07
  3. Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03716856Lead sponsorPhase 1Start 2018-03
  4. A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT06644118Lead (inferred)Phase 1Start 2024-10
  5. APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple MyelomaRecruitingNCT04657861Lead (inferred)Early phase 1Start 2022-05
  6. CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingNCT04662294Lead (inferred)Early phase 1Start 2021-11
  7. A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaNot yet recruitingNCT04670055Lead (inferred)Early phase 1Start 2021-01
  8. A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells TherapyNot yet recruitingNCT04541368Lead (inferred)Early phase 1Start 2020-12
  9. A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaStatus unknownNCT06084962Lead (inferred)Phase 1Start 2023-10
  10. AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple MyelomaStatus unknownNCT05740891Lead (inferred)Phase 1Start 2023-03
  11. A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple MyelomaStatus unknownNCT05712083Lead (inferred)Phase 2Start 2023-01
  12. A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaStatus unknownNCT05430945Lead (inferred)Early phase 1Start 2022-06
  13. A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple MyelomaStatus unknownNCT05016778Lead (inferred)Early phase 1Start 2021-06
  14. CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesStatus unknownNCT04603872Lead (inferred)Early phase 1Start 2020-11
  15. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  16. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  17. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  18. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  19. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  20. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)RecruitingNCT07409246Study sitePhase 1Start 2026-02
  21. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  22. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  23. Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsRecruitingNCT06520176Study sitePhase 3Start 2024-08
  24. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  25. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  26. OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRecruitingNCT06182696Study sitePhase 1/Phase 2Start 2023-10
  27. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Study sitePhase 4Start 2023-10
  28. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRecruitingNCT05565807Study sitePhase 1/Phase 2Start 2023-02
  29. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  30. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  31. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  32. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  33. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  34. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  35. GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06566547Study sitePhase 2Start 2024-08
  36. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  37. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  38. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05719701Study sitePhase 1/Phase 2Start 2023-03
  39. Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological MalignanciesStatus unknownNCT05536154Study siteN/AStart 2022-11
  40. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  41. Phase I Trial of GR1803 Injection in Patients With RRMMCompletedNCT07102706Study sitePhase 1/Phase 2Start 2022-05
  42. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  43. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  44. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  45. Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05346198Study sitePhase 1Start 2021-03
  46. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  47. A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT05011097Study sitePhase 1Start 2021-07
  48. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Study sitePhase 1/Phase 2Start 2021-05
  49. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  50. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  51. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  52. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Study sitePhase 2Start 2020-09
  53. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  54. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Study sitePhase 2Start 2019-01
  55. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  56. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  57. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  58. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  59. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  60. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  61. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  62. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  63. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  64. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Study siteStart 2016-07
  65. Ixazomib Rollover StudyCompletedNCT02924272Study sitePhase 2Start 2016-12
  66. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  67. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  68. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  69. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 5 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 2.2%.

Papers led
5
2021–2025
Trials led
25
any status, ClinicalTrials.gov
Open trials led
13
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025

2 hospitals in Hangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 14

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07246707

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2026-02
    Registry
    NCT07429461

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06793241

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07003737

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Recruiting
    Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07105579

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  6. Recruiting
    CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
    Phase
    Early phase 1
    Started
    2024-05
    Registry
    NCT06346912

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  7. Recruiting
    Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06554626

    Age 40 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  8. Recruiting
    Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06742515

    Age 15 years to 59 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  9. Recruiting
    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06754267

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  10. Recruiting
    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
    Phase
    Early phase 1
    Started
    2020-01
    Registry
    NCT04227015

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  11. Not yet recruiting
    Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06861348

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  12. Not yet recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06902025

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  13. Not yet recruiting
    CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
    Phase
    Early phase 1
    Started
    2020-11
    Registry
    NCT04609241

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  14. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsMRD & relapseChildren
Papers it led5
  1. Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.2026British journal of haematology
  2. Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia.2026Clinical lymphoma, myeloma & leukemia
  3. Safety and efficacy of CD19-targeted CAR-T-cell therapy for patients with relapsed or refractory TCF3-PBX1 fusion gene-positive B-ALL.2025Hematology (Amsterdam, Netherlands)
  4. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.2023Annals of hematology
  5. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.2021Clinical cancer research : an official journal of the American Association for Cancer Research
Chinese-language papers (not in the count)1
  1. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status29
  1. Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCTNot yet recruitingNCT06861348Lead sponsorPhase 2Start 2025-03
  2. Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07003737Lead sponsorN/AStart 2025-02
  3. Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic LeukemiaRecruitingNCT07105579Lead sponsorPhase 2Start 2025-08
  4. Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingNCT06554626Lead sponsorPhase 2Start 2024-08
  5. Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingNCT06754267Lead sponsorPhase 2Start 2024-12
  6. Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALLRecruitingNCT06742515Lead sponsorPhase 2Start 2024-10
  7. KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaRecruitingNCT07246707Lead (inferred)Phase 1Start 2026-01
  8. Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaRecruitingNCT07429461Lead (inferred)Early phase 1Start 2026-02
  9. JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LeukemiaNot yet recruitingNCT06902025Lead (inferred)N/AStart 2025-03
  10. Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06793241Lead (inferred)Early phase 1Start 2025-01
  11. CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHLRecruitingNCT06346912Lead (inferred)Early phase 1Start 2024-05
  12. CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Lead (inferred)Early phase 1Start 2020-11
  13. A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological MalignancyRecruitingNCT04227015Lead (inferred)Early phase 1Start 2020-01
  14. Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic LeukemiaActive, not recruitingNCT07199855Lead (inferred)Phase 2Start 2025-06
  15. Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALLCompletedNCT05350787Lead (inferred)Phase 1Start 2022-03
  16. Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALLStatus unknownNCT05350852Lead (inferred)Phase 1Start 2022-03
  17. Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALLCompletedNCT04788472Lead (inferred)Phase 2Start 2021-03
  18. Natural Killer (NK) Cell Therapy for B-Cell MalignanciesStatus unknownNCT05379647Lead (inferred)Phase 1Start 2021-11
  19. Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALLStatus unknownNCT04740203Lead (inferred)Phase 1/Phase 2Start 2021-01
  20. A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignancyStatus unknownNCT04226989Lead (inferred)Early phase 1Start 2020-02
  21. A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesStatus unknownNCT04532203Lead (inferred)Early phase 1Start 2020-11
  22. A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLStatus unknownNCT04532268Lead (inferred)Early phase 1Start 2020-08
  23. CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesStatus unknownNCT04603872Lead (inferred)Early phase 1Start 2020-11
  24. A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesStatus unknownNCT04532281Lead (inferred)Early phase 1Start 2020-11
  25. A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological MalignanciesCompletedNCT04689204Lead (inferred)Early phase 1Start 2020-12
  26. Study of YK012 in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06580301Study sitePhase 1/Phase 2Start 2024-09
  27. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01
  28. Safety and Efficacy Evaluation of CD19-UCARTSuspendedNCT03229876Study siteN/AStart 2019-06
  29. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 1 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Hangzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06633328

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Not yet recruiting
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07552506

    Age 14 years to 50 years; women only (registered criteria)

    Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 14 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 3.5%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 4420232024: 2220242025: 332025

4 hospitals in Hangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis & prognosisLymphoma & cancer-related HLHTreatment regimens
Departments in papersRheumatology & immunologyPathology / laboratory medicine
Papers it led14
  1. The clinical features and outcomes of aggressive large B cell lymphoma with concomitant hemophagocytic lymphohistiocytosis at diagnosis.2025Annals of hematologyFree full text
  2. Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.2025Blood
  3. Tuberculosis-triggered cytokine storm with hemophagocytic lymphohistiocytosis and tuberculous spondylitis in an apparently immunocompetent host: a case report and literature review.2025Frontiers in immunologyFree full text
  4. Clinical Features of Hepatic Manifestations among Adult Patients with Hemophagocytic Lymphohistiocytosis: A Retrospective Study.2024Acta haematologica
  5. Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.2024Cell transplantationFree full text
  6. Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial.2023American journal of hematology
  7. Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis.2023Annals of hematology
  8. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.2023Cytotherapy
  9. Case Report: Parvovirus B19 infection complicated by hemophagocytic lymphohistiocytosis in a heart-lung transplant patient.2023Frontiers in immunologyFree full text
  10. Hemophagocytic Lymphohistiocytosis Secondary to Disseminated Histoplasmosis in HIV Seronegative Patients: A Case Report and Review of the Literature.2022Frontiers in cellular and infection microbiologyFree full text
  11. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.2022Frontiers in immunologyFree full text
  12. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2022Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
  13. Case Report: Hemophagocytic Lymphocytosis in a Patient With Glutaric Aciduria Type IIC.2021Frontiers in immunologyFree full text
  14. Clinical Value of 18F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study.2021Frontiers in immunologyFree full text
Chinese-language papers (not in the count)1
  1. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review.2023Journal of Zhejiang University. Science. BFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
More papers found outside PubMed (not counted)11
  1. Adult hemophagocytic lymphohistiocytosis: A multicenter retrospective analysis of etiology and impact on survival in China2025Bloodconference-abstract
  2. Early mortality and prognostic factors in diffuse large B-cell lymphoma presenting with hemophagocytic lymphohistiocytosis2025Bloodconference-abstract
  3. Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia2025Bloodconference-abstract
  4. Single-cell transcriptomics reveals monocytic glycolytic reprogramming in lymphoma-associated hemophagocytic lymphohistiocytosis2025Bloodconference-abstract
  5. A Respective Analysis of EBV DNA Status in T/NK Cell Lymphoma Associated-Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  6. Massive Digestive Tract Bleeding Caused by EBV-Triggered Hemophagocytic Lymphohistiocytosis and Digestive Tract Vascular Malformation2022Cancer Research and Cellular Therapeuticsarticle
  7. P1243: RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL2022HemaSphereconference-abstract
  8. Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up2022Bloodarticle
  9. Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial2022Bloodarticle
  10. Warburg effect secondary to diffuse large B‑cell lymphoma-associated hemophagocytic lymphohistiocytosis: a case report2022Research Squarepreprint
  11. Ruxolitinib Combined with Dexamethasone in Adult Patients with Secondary HLH:a Single-Centre Pilot Trial2021Bloodconference-abstract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 4 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

9 hospitals in Hangzhou for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Hangzhou for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 3 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

3 hospitals in Hangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesOptic nerve & visionImagingAntibodies & diagnosis
Departments in papersNeurologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Hangzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesKidney, retroperitoneum & vessels
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution

6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06933563

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia GravisNot yet recruitingNCT06933563Lead (inferred)Early phase 1Start 2025-04
  2. An Exploratory Clinical Study of GC012F Injection for Refractory gMGWithdrawnNCT06419166Lead (inferred)Early phase 1Start 2024-12
  3. Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia GravisStatus unknownNCT05828225Lead (inferred)Phase 1Start 2023-04
  4. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 4 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 2.0%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

3 hospitals in Hangzhou for Wilson disease28 hospitals in China for Wilson disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06650319

    Age 10 years to 60 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Not yet recruiting
    Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07641140

    Age 18 years to 60 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsTreatment (chelation, zinc)

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 2 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

2 hospitals in Hangzhou for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesScreening & diagnosisLiver transplant

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

6 hospitals in Hangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Hangzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Hangzhou for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

9 hospitals in Hangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 112025

11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Arrhythmias and clinical outcomes in Fabry disease with cardiac and renal involvement.2025Orphanet journal of rare diseases
  2. Generation of an induced pluripotent stem cell line (ZJUi007-A) from a 11-year-old patient of Fabry disease.2021Stem cell research
All its trials on ClinicalTrials.gov, any status1
  1. The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry DiseaseNot yet recruitingNCT06819514Study sitePhase 1/Phase 2Start 2025-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Hangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRheumatology & immunology
Papers it led2
  1. Predictors of anti-TNF treatment failure in intestinal Behçet's disease: a multicenter retrospective cohort study.2025Clinical rheumatology
  2. Ischaemic heart disease in Behçet's syndrome: a systematic review and meta-analysis.2022Clinical and experimental rheumatology
Chinese-language papers (not in the count)1
  1. [Pathogenesis and treatment progression of myelodysplastic syndrome combined with Behçet's syndrome].2025Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Earlier papers (2016–2020)1
  1. Is Helicobacter pylori associated with Behçet's syndrome? A meta-analysis.2019Helicobacter
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Hangzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Urinary Sodium Excretion and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.2025American journal of nephrology
  2. Effect of finerenone on proteinuria reduction in IgA nephropathy.2025Renal failure
Earlier papers (2016–2020)4
  1. Updated Oxford classification and the international study of kidney disease in children classification: application in predicting outcome of Henoch-Schönlein purpura nephritis.2019Diagnostic pathology
  2. Changes in the diagnosis of glomerular diseases in east China: a 15-year renal biopsy study.2018Renal failure
  3. Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis.2017Oncotarget
  4. Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.2016Oncotarget
All its trials on ClinicalTrials.gov, any status5
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  4. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  5. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Hangzhou for Gaucher disease41 hospitals in China for Gaucher disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06162338

    Age 18 years to 60 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Hangzhou for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Hangzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 4 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.3%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

11 hospitals in Hangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led4
  1. The fecal microbiota of patients with primary biliary cholangitis (PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC.2024Gut microbes
  2. Single-cell RNA sequencing reveals the pro-inflammatory roles of liver-resident Th1-like cells in primary biliary cholangitis.2024Nature communications
  3. IL-17A produced by invariant natural killer T cells and CD3+ CD56+ αGalcer-CD1d tetramer- T cells promote liver fibrosis in patients with primary biliary cholangitis.2022Journal of leukocyte biology
  4. The Salivary Microbiota of Patients With Primary Biliary Cholangitis Is Distinctive and Pathogenic.2021Frontiers in immunology
Earlier papers (2016–2020)6
  1. TCRβ repertoire of memory T cell reveals potential role for Escherichia coli in the pathogenesis of primary biliary cholangitis.2019Liver international : official journal of the International Association for the Study of the Liver
  2. Reactive lymphoid hyperplasia of the liver: A case report.2019Medicine
  3. No difference in TCRβ repertoire of CD4+ naive T cell between patients with primary biliary cholangitis and healthy control subjects.2019Molecular immunology
  4. Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis.2017Scientific reports
  5. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis.2016Environmental microbiology
  6. Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.2016The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
All its trials on ClinicalTrials.gov, any status4
  1. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  2. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  3. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisActive, not recruitingNCT05050136Study sitePhase 2Start 2021-09
  4. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 4 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 4.0%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

7 hospitals in Hangzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Hangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Whole-genome sequencing identified ALK as a novel susceptible gene of Hirschsprung disease.2025Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Hangzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

浙江大学医学院附属第一医院

First Affiliated Hospital, Zhejiang University

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Affiliated Hospital of Zhejiang University; Branch of First Affiliated Hospital of Zhejiang University; Beilun Branch of the First Affiliated Hospital; Sanmen Branch of the First Affiliated Hospital; First Affiliated Hospital Zhejiang University; Zheda Hospital; Zhejiang Provincial First Hospital

Suggest a correctionDownload the data